Literature DB >> 32425380

Expression Pattern and Prognostic Significance of EVI1 Gene in Adult Acute Myeloid Leukemia Patients with Normal Karyotype.

Irena Marjanovic1, Teodora Karan-Djurasevic1, Tatjana Kostic1, Marijana Virijevic2,3, Nada Suvajdzic-Vukovic2,3, Sonja Pavlovic1, Natasa Tosic1.   

Abstract

According to current criteria, patients with acute myeloid leukemia with normal karyotype (AML-NK) are classified as intermediate risk patients. There is a constant need for additional molecular markers that will help in substratification into more precise prognostic groups. One of the potential new markers is Ecotropic viral integration 1 site (EVI1) transcriptional factor, whose expression is dissregulated in abnormal hematopoietic process. The purpose of this study was to examine EVI1 gene expression in 104 adult AML-NK patients and on 10 healthy bone marrow donors using real-time polymerase chain reaction method, and to evaluate association between EVI1 expression level and other molecular and clinical features, and to examine its potential influence on the prognosis of the disease. Overexpression of EVI1 gene (EVI1 + status) was present in 17% of patients. Increased EVI1 expression was predominantly found in patients with lower WBC count (P = 0.003) and lower bone marrow blast percentage (P = 0.005). EVI1 + patients had lower WT1 expression level (P = 0.041), and were negative for FLT3-ITD and NPM1 mutations (P = 0.036 and P = 0.003). Patients with EVI1 + status had higher complete remission rate (P = 0.047), but EVI1 expression didn't influence overall and disease free survival. EVI1 expression status alone, cannot be used as a new marker for more precise substratification of AML-NK patients. Further investigations conducted on larger number of patients may indicate how EVI1 expression could influence the prognosis and outcome of AML-NK patients, by itself, or in the context of other molecular and clinical parameters. © Indian Society of Hematology and Blood Transfusion 2019.

Entities:  

Keywords:  Acute myeloid leukemia; EVI1 expression; Normal karyotype; Prognosis

Year:  2019        PMID: 32425380      PMCID: PMC7229130          DOI: 10.1007/s12288-019-01227-1

Source DB:  PubMed          Journal:  Indian J Hematol Blood Transfus        ISSN: 0971-4502            Impact factor:   0.900


  35 in total

1.  Oncogenic transcription factor Evi1 regulates hematopoietic stem cell proliferation through GATA-2 expression.

Authors:  Hiromi Yuasa; Yuichi Oike; Atsushi Iwama; Ichiro Nishikata; Daisuke Sugiyama; Archibald Perkins; Michael L Mucenski; Toshio Suda; Kazuhiro Morishita
Journal:  EMBO J       Date:  2005-05-12       Impact factor: 11.598

2.  Risk stratification of intermediate-risk acute myeloid leukemia: integrative analysis of a multitude of gene mutation and gene expression markers.

Authors:  Veronika Rockova; Saman Abbas; Bas J Wouters; Claudia A J Erpelinck; H Berna Beverloo; Ruud Delwel; Wim L J van Putten; Bob Löwenberg; Peter J M Valk
Journal:  Blood       Date:  2011-05-19       Impact factor: 22.113

3.  Three novel cytogenetically cryptic EVI1 rearrangements associated with increased EVI1 expression and poor prognosis identified in 27 acute myeloid leukemia cases.

Authors:  Claudia Haferlach; Ulrike Bacher; Vera Grossmann; Sonja Schindela; Melanie Zenger; Alexander Kohlmann; Wolfgang Kern; Torsten Haferlach; Susanne Schnittger
Journal:  Genes Chromosomes Cancer       Date:  2012-08-08       Impact factor: 5.006

Review 4.  The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.

Authors:  Daniel A Arber; Attilio Orazi; Robert Hasserjian; Jürgen Thiele; Michael J Borowitz; Michelle M Le Beau; Clara D Bloomfield; Mario Cazzola; James W Vardiman
Journal:  Blood       Date:  2016-04-11       Impact factor: 22.113

5.  Molecular stratification model for prognosis in cytogenetically normal acute myeloid leukemia.

Authors:  Carlos M Santamaría; María C Chillón; Ramón García-Sanz; Cristina Pérez; María D Caballero; Fernando Ramos; Alfonso García de Coca; José M Alonso; Pilar Giraldo; Teresa Bernal; José A Queizán; Juan N Rodriguez; Pascual Fernández-Abellán; Abelardo Bárez; María J Peñarrubia; Ana Balanzategui; María B Vidriales; María E Sarasquete; Miguel Alcoceba; Joaquín Díaz-Mediavilla; Jesús F San Miguel; Marcos Gonzalez
Journal:  Blood       Date:  2009-04-27       Impact factor: 22.113

6.  Aberrant expression of ecotropic viral integration site-1 in acute myeloid leukemia and acute lymphoblastic leukemia.

Authors:  Guangsong Su; Xueqi Lian; Dongming Tan; Huiquan Tao; Hong Liu; Suning Chen; Hongchao Yin; Depei Wu; Bin Yin
Journal:  Leuk Lymphoma       Date:  2014-06-25

7.  High EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patients.

Authors:  Sahar Barjesteh van Waalwijk van Doorn-Khosrovani; Claudia Erpelinck; Wim L J van Putten; Peter J M Valk; Sonja van der Poel-van de Luytgaarde; Ronald Hack; Rosalyn Slater; Elisabeth M E Smit; H Berna Beverloo; Gregor Verhoef; Leo F Verdonck; Gert J Ossenkoppele; Pieter Sonneveld; Georgine E de Greef; Bob Löwenberg; Ruud Delwel
Journal:  Blood       Date:  2002-10-03       Impact factor: 22.113

8.  A remote GATA2 hematopoietic enhancer drives leukemogenesis in inv(3)(q21;q26) by activating EVI1 expression.

Authors:  Hiromi Yamazaki; Mikiko Suzuki; Akihito Otsuki; Ritsuko Shimizu; Emery H Bresnick; James Douglas Engel; Masayuki Yamamoto
Journal:  Cancer Cell       Date:  2014-04-03       Impact factor: 31.743

Review 9.  The oncogene and developmental regulator EVI1: expression, biochemical properties, and biological functions.

Authors:  Rotraud Wieser
Journal:  Gene       Date:  2007-04-20       Impact factor: 3.688

10.  EVI1 overexpression reprograms hematopoiesis via upregulation of Spi1 transcription.

Authors:  Edward Ayoub; Michael P Wilson; Kathleen E McGrath; Allison J Li; Benjamin J Frisch; James Palis; Laura M Calvi; Yi Zhang; Archibald S Perkins
Journal:  Nat Commun       Date:  2018-10-12       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.